menu
    • menu
    [{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"ClinSearch | CRM Biometrics | Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Teikoku Seiyaku \/ ClinSearch | CRM Biometrics | Clinigen Group","highestDevelopmentStatusID":"8","companyTruncated":"Teikoku Seiyaku \/ ClinSearch | CRM Biometrics | Clinigen Group"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Patch","sponsorNew":"Teikoku Seiyaku \/ SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Teikoku Seiyaku \/ SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH","highestDevelopmentStatusID":"10","companyTruncated":"Teikoku Seiyaku \/ CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","highestDevelopmentStatusID":"10","companyTruncated":"Teikoku Seiyaku \/ Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services"},{"orgOrder":0,"company":"Teikoku Seiyaku","sponsor":"SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Teikoku Seiyaku","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Teikoku Seiyaku \/ SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services","highestDevelopmentStatusID":"6","companyTruncated":"Teikoku Seiyaku \/ SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services"},{"orgOrder":0,"company":"SocraTec R&D GmbH","sponsor":"Teikoku Seiyaku | SocraMetrics GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Esflurbiprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"SocraTec R&D GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"SocraTec R&D GmbH \/ Teikoku Seiyaku | SocraMetrics GmbH","highestDevelopmentStatusID":"6","companyTruncated":"SocraTec R&D GmbH \/ Teikoku Seiyaku | SocraMetrics GmbH"}]

    Find Clinical Drug Pipeline Developments & Deals for Esflurbiprofen

    Menu

    Esflurbiprofen

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions

                            Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Contusions.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2025

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Clinsearch GmbH | CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Assess the Effect of the Special Condition on the Pharmacokinetics and Tolerability of the Esflurbiprofen T...

                            Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2025

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Study Phase : Phase III

                            Sponsor : CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.

                            Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ankle Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Orthopedics/Orthopedic Surgery

                            Highest Development Status : Phase III

                            Sponsor : CRM Biometrics | SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services | Clinsearch GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Assess the Bioavailability of TK-254RX in Comparison with Oral Flurbiprofen Tablets and the Adhesion of TK-...

                            Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 12, 2025

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : SocraTec R&D GmbH | SocraMetrics GmbH | HWI Pharma Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed

                            Teikoku Seiyaku

                            Japan arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase II

                            Sponsor : ClinSearch | CRM Biometrics | Clinigen Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain

                            Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Soft Tissue Injuries.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2021

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase II

                            Sponsor : ClinSearch | CRM Biometrics | Clinigen Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SocraTec R&D GmbH

                            Country arrow
                            FNCE
                            Not Confirmed

                            SocraTec R&D GmbH

                            Country arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Teikoku Seiyaku | SocraMetrics GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            S-flurbiprofen Bioavailability Trial to Compare a Newly Developed Patch vs. a Marketed Tablet

                            Details : Esflurbiprofen is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 10, 2020

                            Lead Product(s) : Esflurbiprofen

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Teikoku Seiyaku | SocraMetrics GmbH

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth